Business Context and Reporting Period
This Form 8-K Current Report was filed by NewAmsterdam Pharma Company N.V. on July 16, 2026. The registrant is a clinical-stage biotechnology company incorporated in The Netherlands, with ordinary shares and warrants trading on The Nasdaq Stock Market LLC under the symbols NAMS and NAMSW, respectively.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
The primary material change disclosed is the departure of a senior executive:
- Resignation: Douglas Kling notified the Company of his resignation as Chief Operating Officer, effective August 14, 2026.
- Reason: Mr. Kling is departing to be appointed as the chief executive officer of another clinical-stage biotech company.
Outlook, Management Commentary, and Risks
Management indicated the following regarding the transition:
- Separation Agreement: The Company expects to enter into a separation agreement with Mr. Kling.
- Advisory Role: The Company expects to enter into an advisor agreement for Mr. Kling to provide transition and advisory services related to the PREVAIL clinical trial of obicetrapib and other clinical programs, subject to mutual agreement of terms.
- Future Disclosure: Material terms of the separation and advisor agreements will be disclosed in an amendment to this Current Report.
Investor Verification Checklist
- Verify the terms of the separation agreement and any severance payments once disclosed in the 8-K amendment.
- Confirm the scope and duration of the advisory agreement regarding the PREVAIL clinical trial.
- Monitor for the announcement of an interim or permanent replacement for the Chief Operating Officer role.
- Review the impact of this leadership change on the timeline for the obicetrapib clinical programs.